^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RAB22A underexpression

    i
    Other names: RAB22A, RAB22A, Member RAS Oncogene Family, Ras-Related Protein Rab-22A, Rab-22, GTP-Binding Protein RAB22A, RAB22
    Entrez ID:
    57403
    1year
    RAB22A As a Predictor of Exosome Secretion in the Progression and Relapse of Multiple Myeloma (ASH 2023)
    We screened sensitive drugs according to the difference of IC50 values between high and low RAB22A groups, and found that cisplatin, Doxorubicin and bcl-2 inhibitors had higher sensitivity in low RAB22A group. RAB22A is a potential therapeutic target to improve the prognosis of MM, which is closely related to exosome secretion, EMT and immune cell infiltration.
    IO biomarker
    |
    CD4 (CD4 Molecule) • RAB22A (RAB22A, Member RAS Oncogene Family) • METTL14 (Methyltransferase 14) • RBM15 (RNA Binding Motif Protein 15) • VIRMA (Vir Like M6A Methyltransferase Associated)
    |
    RAB22A underexpression
    |
    cisplatin • doxorubicin hydrochloride